CORALVILLE, IA — Digital Diagnostics Inc., a global healthcare autonomous artificial intelligence company formerly known as IDx, has acquired 3Derm Systems Inc. of Boston.
The rebrand of IDx to Digital Diagnostics reflects its expanded platform of autonomous AI products in multiple medical specialties. The company’s flagship product, IDx-DR, “was the first autonomous AI system De Novo authorized by the FDA in any field of medicine,” according to a press release announcing the deal. The system diagnoses diabetic retinopathy and diabetic macular edema.
With the acquisition of 3Derm, the Digital Diagnostics platform will include telemedicine capabilities for dermatology, 3DermTriage, in preparation for FDA authorization of its autonomous AI skin cancer diagnostic system, 3DermSpot.
Financial terms of the transaction were not disclosed.
In “autonomous AI, “it is the computer, not the clinician, making the medical decisions, enabling patients to obtain diagnoses for serious conditions when and where they receive medical care.” according to the release.
Advertisement
“There is too much needless suffering from treatable illnesses, and this happens more in populations that do not have equitable access to healthcare, and particularly to specialist physicians,” said Michael Abramoff, MD, PhD, founder and executive chairman of Digital Diagnostics. “Our autonomous systems allow frontline care providers to instantaneously diagnose serious conditions, refer patients who need specialist treatment faster, and improve long-term patient outcomes.”
Digital Diagnostics was founded in 2010 by Abramoff, a practicing, fellowship-trained retina specialist ophthalmologist, neuroscientist and computer engineer who developed a patented biomarker-based approach to build AI algorithms that perform cognitively complex tasks.
To make instantaneous diagnoses, both IDx-DR and 3DermSpot use high quality images of the eyes and skin coupled with autonomous AI; the system is operated by existing primary care clinic staff.
Digital Diagnostics products “are in use by the largest and most prestigious health systems in the U.S. and globally,” according to the release.
“By using Digital Diagnostics’ autonomous AI platform, 3DermSpot decreases the time it takes to put their life saving device in the hands of frontline care providers,” said John Bertrand, CEO, Digital Diagnostics. “Expanding the specialties our products cover allows our customers to use our platform as their one stop shop for autonomous AI diagnostics at the point-of-care.”
